Antiviral Drugs - Chile | Statista Market Forecast

The Antiviral Drugs market in Chile is expected to experience significant growth in the coming years.
According to projections, the revenue in this market is set to reach US$98.79m by 2024.
Furthermore, it is anticipated that there will be a steady annual growth rate of 1.65% from 2024 to 2029, resulting in a market volume of US$107.20m by the end of the forecast period.
When compared globally, it is interesting to note that United States is expected to generate the highest revenue in the Antiviral Drugs market.
In 2024, the projected revenue for the United States is estimated to be US$30.64bn.
This highlights the significant market potential and demand for antiviral drugs United States.
Chile's antiviral drug market is experiencing a surge in demand due to the country's proactive approach in combating viral outbreaks.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

Antiviral drugs are pharmaceuticals used to treat viral infections by inhibiting the development of viruses. In Chile, the Antiviral Drugs market is witnessing a steady growth rate.

Customer preferences: The increasing prevalence of viral infections in Chile is driving the demand for Antiviral Drugs. The customers in Chile are becoming more aware of the benefits of Antiviral Drugs in treating viral infections and are willing to spend on these medications. Moreover, the rise in the geriatric population and the increasing incidence of chronic diseases are also contributing to the growth of the Antiviral Drugs market in Chile.

Trends in the market: The Antiviral Drugs market in Chile is witnessing a growing trend of research and development activities to develop new and improved Antiviral Drugs. The market players in Chile are investing heavily in research and development to develop innovative drugs that can effectively treat viral infections. Additionally, the market is also witnessing a trend of collaborations and partnerships between pharmaceutical companies to develop new drugs and expand their market presence.

Local special circumstances: Chile has a well-developed healthcare system that provides universal healthcare coverage to its citizens. The government of Chile has implemented several initiatives to promote the use of generic drugs and reduce healthcare costs. This has led to an increase in the availability of Antiviral Drugs at affordable prices, thereby driving the growth of the market.

Underlying macroeconomic factors: Chile is a developing country with a stable economy and a growing middle class. The country has a high Human Development Index (HDI) and is ranked as a high-income economy by the World Bank. The stable economic conditions in Chile have led to an increase in disposable income, which has contributed to the growth of the Antiviral Drugs market. Additionally, the government of Chile has implemented several policies to promote the growth of the pharmaceutical industry, which has also positively impacted the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.